Business Context and Reporting Period
This Form 8-K was filed by AcelRx Pharmaceuticals, Inc. on March 14, 2016, reporting events occurring on March 9, 2016. The filing details an amendment to a Material Definitive Agreement with Patheon Pharmaceuticals, Inc.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a contractual amendment rather than financial performance.
Material Changes
The Company amended its Manufacturing Services Agreement (MSA) with Patheon Pharmaceuticals, Inc. to:
- Expand the Territory to include the European Union, Switzerland, Liechtenstein, Norway, Iceland, and Australia.
- Include references to relevant regulatory agencies within the new Territory.
- Update the product list and specifications.
- Identify minimum run quantities, annual volume, and pricing.
- Identify EU stability testing and other quality-related measures.
Guidance, Outlook, and Risks
The filing contains no management guidance, financial outlook, or discussion of risks and contingencies. The full text of the amendment is referenced as an exhibit to be filed in the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2016.
Investor Verification Checklist
- Verify the specific pricing and annual volume commitments in the full MSA amendment.
- Confirm the updated product list and specifications included in the agreement.
- Review the upcoming Form 10-Q for the quarter ended March 31, 2016, to access the full exhibit.